貨號(hào)：GS40134

Cirevetmab (ZTS-00521426) is an investigational caninized monoclonal antibody classified as an immunomodulator. It is developed for veterinary use, specifically targeting a key cytokine involved in immune regulation, fibrosis, and inflammation. Its primary therapeutic goal is to modulate excessive or dysregulated immune responses in dogs, potentially for conditions where this pathway plays a central role, such as chronic inflammatory diseases or fibrotic disorders.